Skip to main content
AXGN logo

AxoGen, Inc. (AXGN) Stock: Price, Forecast & Analyst Target

AxoGen, Inc. (AXGN) — MoonshotScore 38/100 (Weak band), calculated Nov 18, 2026. Price $56.35 (-1.05%), as of the Nov 19, 2026 trading session; market cap $3.37B.

Educational signal · not a buy or sell recommendation · How to read this

$56.35 −$0.60 (-1.05%) Market Cap $3.37B

AxoGen, Inc. · AXGN · NASDAQ

AxoGen, Inc. focuses on developing and marketing surgical solutions for peripheral nerve damage. Their product portfolio includes nerve grafts, connectors, protectors, and soft tissue membranes, serving hospitals and surgeons globally.

Price as of Nov 19, 2026

Key Statistics

38 of 100

MoonshotScore v2 · AxoGen (AXGN)

Weak
Business Quality Solid (71)
Financial Safety Sound (73)
Valuation Rich (39)
Growth Durability Growing (61)
Momentum Surging (96)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

High quality and a strong balance sheet, but an expensive valuation. The score also carries a risk penalty for losses on top of negative retained earnings. Business Quality: Solid; Financial Safety: Sound; Valuation: Rich; Growth Durability: Growing; Momentum: Surging.

  • EPS beat 0 of the last 4 reports
  • Altman Z 37.20 · Piotroski F 4
  • ROE -10.3% · ROA -2.3% · current ratio 12.02

Helping: business quality, balance-sheet strength, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for AXGN (58 recorded, newest six shown)
RecordedScoreBand
40Weak
38Weak
38Weak
38Weak
38Weak
38Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$56.35
Change on the day-1.05%
52-week range$23.00 – $59.72
Market capitalisation$3.37B—
Price / earnings (trailing)59.60
Shares traded on the day1.09M

Price & events

Other perspectives

Council score for AxoGen (AXGN): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Moderate
Financial Safety Moderate
Valuation Weak
Growth Durability Moderate
Momentum Strong

Legends Council

6 lenses, 6 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Simons-style lens (simulated) Jim Simons Favorable read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Nov 21, 2026

Munger's Mindset

Balance Sheet & Valuation

Financial Health Neutral
Margin of Safety Overvalued
Profit Margin Weak
Revenue Growth Strong
Debt/Equity Strong
ROE Negative
Gross Margin Strong

Read on: Nov 20, 2026

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

Four of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens, Griffin-style lens, Simons-style lens and Englander-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

The Munger lens reads the current price as overvalued against its own estimate of value.

Readings on this page are from Nov 21, 2026, except a card that shows its own read date.

1 · What is it?

What is AxoGen (AXGN), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. AxoGen, Inc. (AXGN) is listed on NASDAQ. It employs 622 people and is led by Michael D. Dale. The market values it at $3.37B.

2 · Latest results

What do the latest results show for AxoGen (AXGN)?

Short answer · as of

Against analyst estimates the company has EPS beat 0 of the last 4 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2025$60M$708,000$0.01 (diluted)
Q4 FY2025$60M-$13M-$0.28 (diluted)
Q1 FY2026$61M-$20M-$0.38 (diluted)
Q2 FY2026$70M-$2M-$0.03 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for AxoGen (AXGN)?

Short answer · as of

The MoonshotScore pillars rate business quality, balance-sheet strength, positive momentum as strengths. The distress and quality screens read Altman Z 37.20 · Piotroski F 4. Trailing ratios: ROE -10.3% · ROA -2.3% · current ratio 12.02.

Data-derived red flags

  • Negative return on equity (-10.3%) — the business is not currently generating profit on shareholder capital.
  • Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
4 · What to check next?

What should you watch next at AxoGen (AXGN)?

Short answer · as of

Current published price targets run low $53.00 · high $65.00 · consensus $58.13 · median $57.50 against a quoted price of $56.35 (as of Nov 19, 2026).

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does AxoGen compare with its peers?

Short answer

AxoGen's score ranks 11th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Inspire Medical Systems, Inc. (INSP) Same industry, near in market value$56.28 Nov 19, 2026$1.63B94 5-pillar Nov 18, 2026
Globus Medical, Inc. (GMED) Same industry, near in market value$68.60 Nov 19, 2026$9.09B94 5-pillar Nov 18, 2026
LivaNova PLC (LIVN) Same industry, near in market value$92.07 Nov 19, 2026$5.07B88 5-pillar Nov 18, 2026
UFP Technologies, Inc. (UFPT) Same industry, near in market value$298.93 Nov 19, 2026$2.32B87 5-pillar Nov 18, 2026
Insulet Corporation (PODD) Same industry, near in market value$137.23 Nov 19, 2026$9.52B85 5-pillar Nov 18, 2026
CONMED Corporation (CNMD) Same industry, near in market value$46.38 Nov 19, 2026$1.38B79 5-pillar Nov 18, 2026
Bio-Rad Laboratories, Inc. (BIO) Same industry, near in market value$367.50 Nov 19, 2026$9.88B77 5-pillar Nov 18, 2026
TransMedics Group, Inc. (TMDX) Same industry, near in market value$94.02 Nov 19, 2026$3.27B68 5-pillar Nov 18, 2026
Integer Holdings Corporation (ITGR) Same industry, near in market value$126.97 Nov 19, 2026$4.32B68 5-pillar Nov 18, 2026
Bruker Corporation (BRKR) Same industry, near in market value$62.10 Nov 19, 2026$9.48B59 5-pillar Nov 18, 2026
AxoGen (AXGN) — this page$56.35$3.37B38
Establishment Labs Holdings Inc. (ESTA) Same industry, near in market value$69.61 Nov 19, 2026$2.08B35 5-pillar Nov 18, 2026
iRhythm Technologies, Inc. (IRTC) Same industry, near in market value$94.24 Nov 19, 2026$3.17B33 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$53.00 – $65.00
Consensus target
$58.13
Median target
$57.50

Consensus record · Captured .

Measured against a quoted price of $56.35 (as of Nov 19, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Sep 2, 2026

Transactions
29
Identified insiders
8
Purchases
0
Sales
4
Other transactions
25

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held AXGN in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported AXGN in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about AxoGen (AXGN)?

Read these with our analysis →

Investor Questions: AXGN Stock

These answers are editorial: 1 of these 9 answers is drawn from the AXGN research dossier (written May 9, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for AXGN?

AXGN carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. AxoGen, Inc. focuses on developing and marketing surgical solutions for peripheral nerve damage.

Is AXGN a good stock to buy?

Stock Expert AI does not rate AXGN buy, sell or hold. AxoGen, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the AXGN stock price today?

The last price recorded for AxoGen, Inc. (AXGN), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the AXGN price target?

The analyst consensus price target for AxoGen, Inc. (AXGN), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

What does AxoGen, Inc. do?

AxoGen, Inc. specializes in developing and marketing surgical solutions for peripheral nerve repair. Their primary focus is on addressing physical damage or transection to peripheral nerves through a range of products.

What are the key factors to evaluate for AXGN?

AxoGen, Inc. (AXGN) holds a MoonshotScore in the low range. To weigh it, compare the trailing P/E under Price & valuation with the analyst view under Analyst targets & estimates on this page. Focus on the niche market of peripheral nerve repair, positioning AxoGen as a specialized player. Not financial advice.

How frequently does AXGN data refresh on this page?

AXGN's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven AXGN's recent stock price performance?

AxoGen, Inc. (AXGN) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative product portfolio addressing unmet needs in peripheral nerve repair. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider AXGN overvalued or undervalued right now?

The trailing P/E of AxoGen, Inc. (AXGN) is listed under Price & valuation, and the analyst consensus target under Analyst targets & estimates, on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 9, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 18 figures on this page — 12 from Financial Modeling Prep (FMP), 5 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.